(malignant mixed mesodermal tumor; MMMT)
,
1% .
,
( )
,
( , )
.1,2
, .
,
12 .1-3
1
.
: , 63
: 5-0-0-5
: 16 43
.
: , ,
: .
: 15 ,
2 ,
. :
, 151 cm, 50 kg, 120/
80 mmHg, 76 /min, 20 /min, 36
.
Department of Obstetrics and Gynecology, Busan Paik Hospital, College of Medicine, InJe University, Busan, Korea
Malignant mixed mesodermal tumor (MMMT) of the ovary is very rare, constituting 1% of all primary ovarian tumors.
MMMT is a highly aggressive and rapidly progressive tumor with a poor long-term prognosis. Though aggressive surgery is generally felt to be indicated for this tumor, there is no uniform opinion about adjuvant therapy.
We have experienced a case of primary malignant mixed mesodermal tumor of the ovary and report it with a brief review of literatures.
Key Words : Malignant mixed mesodermal tumor, Ovary
, 10×10 cm .
13.3 gm/dL, 37.2%,
4,800/mm3, 289,000/mm3 , ,
, , , X-
, .
CA-125 201.4 U/ml .
:
10.3×7.8 cm .
10×5×10 cm ,
, .
:
.
,
. 500 cc
, 1.0 cm , 2 cm
1.5 cm .
, , ,
, ,
.
:
7.5×5.0×5.0 cm, 9.8×4.5×4.5 cm ,
. (Fig. 1).
(Fig. 2A).
, (Fig. 2B).
Cytokeratin (Fig. 3A) EMA
(Epithelial membrane antigen) ,
Vimentin
6 0.8×0.5 cm ,
1.0 cm . ,
,
.
: , 6
4 (PAC
Cisplatin, Adriamycin, Cyclophosphamide)
, CA 125 4
CA 125 29.28 U/ml .
,
( )
,
( , )
.2
, , , ,
.
.
1% .1
60-70
.4 ,
,4 (FIGO stage and )
.4
.
( ,
, ,
, ,
) ,
.7-9
, .4
. ,
VAC 16.7%,2 ifosfamide/
mesna 20%,10 platinum-
based 64-85%,
3,4,9,11-13
paclitaxel/platinum 72%
14 . ,
cisplatin/irinotecan mesna, ifosfamide, adriamycin, dacarbazine (MAID)
.15,16
( , ,
, , ,
) cisplatin,
adriamycin, cyclophosphamide (PAC) .
, ,
, , ,
, ,
,4-7,12 CA-125
.13,17
1% . .
.
1
.
,
